Balchem Q3 2025: record sales $267.6M, adj. EPS $1.35, all segments grow

BALCHEM CORP

2025-Q3 EPS reported $3.54 revenue$773,544,000

Record net sales $267.6M (+11.5% YoY); GAAP EPS $1.24 vs $1.03; adjusted EPS $1.35 vs $1.13.
Record adjusted EBITDA $71.4M (+11.0% YoY); free cash flow $50.7M.
All three segments achieved sales and earnings growth; new NY microencapsulation plant to double capacity.
Net debt reduced to $88.9M, leverage 0.3x; repaid $36M on revolver during Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.